Search Result

Results for "

Nephropathy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Aldose Reductase (2) AMPK (3) Androgen Receptor (1) Angiotensin Receptor (6) Angiotensin-converting Enzyme (ACE) (2) Apoptosis (4) Autophagy (1) Biochemical Assay Reagents (2) CCR (2) Cytochrome P450 (1) Endogenous Metabolite (5) Glucosidase (1) Guanylate Cyclase (2) Integrin (1) MAP3K (1) Mineralocorticoid Receptor (3) Mitochondrial Metabolism (1) Mitophagy (1) MMP (2) NADPH Oxidase (2) Neuropeptide Y Receptor (1) NO Synthase (1) Nuclear Factor of activated T Cells (NFAT) (2) p38 MAPK (2) Phosphatase (1) Progesterone Receptor (1) Renin (1) Tie (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (12) Endocrinology (1) Inflammation/Immunology (7) Metabolic Disease (36) Neurological Disease (2)

By Targets:

Adenosine Receptor (1)

Aldose Reductase (2)

AMPK (3)

Androgen Receptor (1)

Angiotensin Receptor (6)

Angiotensin-converting Enzyme (ACE) (2)

Apoptosis (4)

Autophagy (1)

Biochemical Assay Reagents (2)

CCR (2)

Cytochrome P450 (1)

Endogenous Metabolite (5)

Glucosidase (1)

Guanylate Cyclase (2)

Integrin (1)

MAP3K (1)

Mineralocorticoid Receptor (3)

Mitochondrial Metabolism (1)

Mitophagy (1)

MMP (2)

NADPH Oxidase (2)

Neuropeptide Y Receptor (1)

NO Synthase (1)

Nuclear Factor of activated T Cells (NFAT) (2)

p38 MAPK (2)

Phosphatase (1)

Progesterone Receptor (1)

Renin (1)

Tie (1)

By Research Areas:

Cancer (5)

Cardiovascular Disease (12)

Endocrinology (1)

Inflammation/Immunology (7)

Metabolic Disease (36)

Neurological Disease (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12738

PF-3882845	Mineralocorticoid Receptor Progesterone Receptor	Cardiovascular Disease Metabolic Disease
PF-3882845 is a remarkably high affinity selective and orally efficacious mineralocorticoid receptor (MR binding IC₅₀=2.7 nM) antagonist for hypertension and nephropathy. PF-3882845 also binds to progesterone receptor (PR) with the binding IC₅₀ of 310 nM .

HY-W047156

Allantoxanamide	Biochemical Assay Reagents	Metabolic Disease
Allantoxanamide is a uricase inhibitor. Allantoxanamide-induced rats serve as animal models for studying purine biosynthesis, drug-induced hyperuricemia and hyperuricosuria, and related nephropathy .

HY-P5309

(Thr(GalNAc)4,7,15,Ser(GalNAc)9,11)-IgA1 Hinge Region Peptide	Biochemical Assay Reagents	Inflammation/Immunology
(Thr(GalNAc)4,7,15,Ser(GalNAc)9,11)-IgA1 Hinge Region Peptide is a synthetic glycopeptide and can be used for detection of gender difference and epitope specificity of IgG antibody activity against IgA1 hinge portion in IgA nephropathy patients .

HY-117962

(Rac)-BI 703704	Guanylate Cyclase	Metabolic Disease
(Rac)-BI 703704 is a potent soluble guanylyl cyclase (sGC) activator. (Rac)-BI 703704 reduces progression of renal damage in the ZSF1 rat, and highlight the potential of sGC activation as an effective therapy for diabetic nephropathy .

HY-111327

Valibose	Glucosidase	Metabolic Disease
Valibose is analpha-glucosidaseinhibitor, and ameliorates the metabolic disorder of glucose and lipids and the nephropathy in Streptozotocin (HY-13753)-induced diabetic rats .

HY-162325

WJ-39	Aldose Reductase Mitochondrial Metabolism Apoptosis Mitophagy	Metabolic Disease
WJ-39 is an orally active aldose reductase (AR) inhibitor. WJ-39 improves tubular damage in diabetic nephropathy rats by activating PINK1/Parkin signaling, promoting mitophagy, and attenuating apoptosis .

HY-131542

APPA	Aldose Reductase Apoptosis	Metabolic Disease
APPA is an aldose reductase inhibitor. APPA can effectively prevent apoptosis and the symptoms of Streptozotocin (HY-13753)-induced diabetes by inhibiting the polyol pathway in rats. APPA has the potential for diabetic nephropathy (DN) research .

HY-117962A

BI 703704	Guanylate Cyclase	Metabolic Disease
BI 703704 is a potent soluble guanylate cyclase (sGC) activator. BI 703704 inhibits the progression of diabetic nephropathy in the ZSF1 rat .

HY-117623

PF-06685249 PF-249	AMPK	Metabolic Disease
PF-06685249 (PF-249) is a potent and orally active allosteric AMPK activator with an EC₅₀ of 12 nM for recombinant AMPK α1β1γ1. PF-06685249 can be used for diabetic nephropathy research .

HY-149770

CYP4A11/CYP4F2-IN-2	Cytochrome P450	Metabolic Disease
CYP4A11/CYP4F2-IN-2 (compound 15) is an orally available inhibitor of CYP4A11/4F2 with IC₅₀s of 120 nM and 220 nM, respectively. CYP4A11/CYP4F2-IN-2 inhibits 20-HETE production in rat kidney and has potential inhibitory effects on diabetic nephropathy and autosomal dominant polycystic kidney disease .

HY-N7675

Flavanomarein	Others	Cardiovascular Disease Metabolic Disease
Flavanomarein is a predominant flavonoid of Coreopsis tinctoria Nutt with protective effects against diabetic nephropathy. Flavanomarein has good antioxidative, antidiabetic, antihypertensive and anti-hyperlipidemic activities .

HY-N7675A

(2R)-Flavanomarein	Others	Metabolic Disease
(2R)-Flavanomarein is a predominant flavonoid of Coreopsis tinctoria Nutt with protective effects against diabetic nephropathy. (2R)-Flavanomarein has good antioxidative, antidiabetic, antihypertensive and anti-hyperlipidemic activities .

HY-B1451

Imidapril hydrochloride TA-6366	Angiotensin-converting Enzyme (ACE) MMP	Cardiovascular Disease Metabolic Disease
Imidapril hydrochloride (TA-6366) is an orally active angiotensin-converting enzyme (ACE) and MMP-9 inhibitor. Imidapril hydrochloride suppresses the conversion of angiotensin I to angiotensin II and thereby reduces total peripheral resistance and systemic blood pressure. Imidapril hydrochloride can be used for hypertension, type 1 diabetic, nephropathy and chronic heart failure research .

HY-B1451A

Imidapril TA-6366 free base	Angiotensin-converting Enzyme (ACE) MMP	Cardiovascular Disease Metabolic Disease
Imidapril (TA-6366 free base) is an orally active angiotensin-converting enzyme (ACE) and MMP-9 inhibitor. Imidapril suppresses the conversion of angiotensin I to angiotensin II and thereby reduces total peripheral resistance and systemic blood pressure. Imidapril can be used for hypertension, type 1 diabetic, nephropathy and chronic heart failure research .

HY-120270

PF-06679142	AMPK	Metabolic Disease
PF-06679142 (Compound 10) is a potent, orally active AMPK activator with an EC₅₀ of 22 nM against α1β1γ1-AMPK. PF-06679142 can be used for diabetic nephropathy research .

HY-101499

GKT136901 1 Publications Verification	NADPH Oxidase	Neurological Disease Metabolic Disease Inflammation/Immunology
GKT136901 is a potent, selective and orally active inhibitor of NADPH oxidase (NOX1/4), with K_is of 160 and 165 nM, respectively. GKT136901 is also a selective and direct scavenger of peroxynitrite. GKT136901 can be used for the research of diabetic nephropathy, stroke, and neurodegeneration. GKT136901 also has anti-inflammatory activity .

HY-101499A

GKT136901 hydrochloride 1 Publications Verification	NADPH Oxidase	Neurological Disease Metabolic Disease
GKT136901 hydrochloride is a potent, selective and orally active inhibitor of NADPH oxidase (NOX1/4), with K_is of 160 and 165 nM, respectively. GKT136901 hydrochloride is also a selective and direct scavenger of peroxynitrite. GKT136901 hydrochloride can be used for the research of diabetic nephropathy, stroke, and neurodegeneration. GKT136901 hydrochloride also has anti-inflammatory activity .

HY-101986A

BIIE-0246 hydrochloride AR-H 053591 hydrochloride	Neuropeptide Y Receptor	Metabolic Disease
BIIE-0246 hydrochloride (AR-H 053591 hydrochloride) is a potent and selective NPY2R (neuropeptide Y receptor 2) antagonist with an IC₅₀ value of 15 nM for rat [ ¹²⁵I]PYY_3-36. BIIE-0246 hydrochloride decreases the expression of p-AKT S473, P-p44/42 MAPK under the NPY-stimulated. BIIE-0246 hydrochloride reduces albuminuria in ADR nephropathy .

HY-122963

Danshenol B	Adenosine Receptor	Metabolic Disease
Danshenol B is a diterpenoid. Danshenol B has strong aldose reductase (AR) inhibitory activity with IC₅₀ value of 0.042μM. Danshenol B can be used for the research of diabetic related complication resulted by metabolic abnormality, such as cataracts, retinopathy, neuropathy, and nephropathy .

HY-117621

PF-04634817	CCR	Metabolic Disease
PF-0463481 is a potent and orally active dual CCR2/CCR5 antagonist with comparable human and rodent CCR2 potency (rat IC₅₀=20.8 nM), and displays 10-20 fold less rodent CCR5 potency (rat IC₅₀=470 nM). PF-0463481 is safe and well-tolerated and has the potential for the study of diabetic nephropathy .

HY-117621A

PF-04634817 succinate	CCR	Metabolic Disease
PF-0463481 succinate is a potent and orally active dual CCR2/CCR5 antagonist with comparable human and rodent CCR2 potency (rat IC₅₀=20.8 nM), and displays 10-20 fold less rodent CCR5 potency (rat IC₅₀=470 nM). PF-0463481 succinate is safe and well-tolerated and has the potential for the study of diabetic nephropathy .

HY-145552

Azilsartan mepixetil QR-01019	Angiotensin Receptor	Cardiovascular Disease
Azilsartan mepixetil is the antagonist of angiotensin II receptor. Azilsartan mepixetil has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil achieves ideal protective effect for heart and kidney functions. Azilsartan mepixetil has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A) .

HY-157129

AMPK-α1β1γ1 activator 1	AMPK	Cardiovascular Disease
AMPK-α1β1γ1 activator 1 (M1) is an acyl glucuronide metabolite of Indole-3-carboxylic Acid-based AMPK activator. AMPK-α1β1γ1 activator 1 can selectively activated human β1 isoforms with an EC₅₀ value of 38.1nM. AMPK-α1β1γ1 activator 1 can direct binding with human AMPK α1β1γ1 isoform. AMPK-α1β1γ1 activator 1 can be used for the research of diabetic nephropathy .

HY-101581

Bucloxic acid 804CB; Bucloxonic acid; Esfar	Others	Inflammation/Immunology
Bucloxic acid is an anti-inflammatory pyrrazole derivative. Bucloxic acid can be used in the treatment of chronic glomerular nephropathies.

HY-P1572

Handle region peptide, rat	Renin	Inflammation/Immunology
Handle region peptide, rat is a prorenin receptor antagonist, suppresses the progression of diabetic nephropathy and has anti-inflammatory in the eye.

HY-109002

Apararenone MT-3995	Mineralocorticoid Receptor	Cardiovascular Disease Metabolic Disease
Apararenone (MT-3995) is a novel non-steroidal mineralocorticoid receptor antagonists under development for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis.

HY-N2608

7-O-Ethylmorroniside	Others	Metabolic Disease
7-O-Ethylmorroniside is a iridoid glucoside from the fruit of Cornus officinalis which is a traditional medicine in China and used for the reserch of kidney diseases, including diabetic nephropathy .

HY-P1430

11R-VIVIT Cell permeable NFAT inhibitor	Nuclear Factor of activated T Cells (NFAT)	Metabolic Disease
11R-VIVIT is a cell-permeable nuclear factor of activated T cells (NFAT) inhibitor. 11R-VIVIT can be used for the research of podocyte and diabetic nephropathy .

HY-P1430A

11R-VIVIT TFA 5+ Cited Publications Cell permeable NFAT inhibitor TFA	Nuclear Factor of activated T Cells (NFAT)	Metabolic Disease
11R-VIVIT TFA is a cell-permeable nuclear factor of activated T cells (NFAT) inhibitor. 11R-VIVIT TFA can be used for the research of podocyte and diabetic nephropathy .

HY-18938

Selonsertib Maximum Cited Publications 13 Publications Verification GS-4997	MAP3K Apoptosis	Cancer
Selonsertib (GS-4997), an orally bioavailable, selective apoptosis signal-regulating kinase 1 (ASK1) inhibitor with a pIC₅₀ of 8.3, has been evaluated as an experimental treatment for diabetic nephropathy and kidney fibrosis.

HY-W010271

(2S,3R,4S)-4-Hydroxyisoleucine (2S,3R,4S)-4-Hydroxy-L-isoleucine; Hydroxyisoleucine	Others	Metabolic Disease
(2S,3R,4S)-4-Hydroxyisoleucine is an orally active compound isolated from Trigonella foenum-graecum, with anti-diabetes and anti-diabetic nephropathy activity .

HY-114683

KS370G	Others	Cardiovascular Disease
KS370G is an orally active hypoglycemic and cardiovascular protective agent. KS370G improves left ventricular hypertrophy and function in pressure-overload mice heart. KS370G reduces renal obstructive nephropathy .

HY-W166297

Esculin sesquihydrate	p38 MAPK	Cancer
Esculin sesquihydrate, a fluorescent coumarin glucoside, is an active ingredient of ash bark. Esculin sesquihydrate ameliorates cognitive impairment in experimental diabetic nephropathy (DN), and exerts anti?oxidative stress and anti?inflammatory effects, via the MAPK signaling pathway .

HY-B1041

Aminoguanidine hydrochloride 2 Publications Verification Pimagedine hydrochloride; GER-11; Aminoguanidinium chloride	NO Synthase Apoptosis	Endocrinology
Aminoguanidine hydrochloride (Pimagedine hydrochloride) is an inhibitor of diamine oxidase and nitric oxide synthase. Aminoguanidine hydrochloride has a dose-dependent inhibitory effect on apoptosis induced by Doxorubicin (HY-15142). Aminoguanidine hydrochloride has antioxidant properties. Aminoguanidine hydrochloride can be used in diabetic nephropathy research .

HY-147152

1-Myristoyl-3-chloropropanediol	Others	Others
1-Myristoyl-3-chloropropanediol is a 3-monochloropropanediol (3-MCPD) fatty acid ester. 3-MPCD causes nephropathy and tubular hyperplasia and adenomas by chronic oral administration; also reduces fertility, or provokes infertility in rats and suppresses the immune function .

HY-B0561

Spironolactone 3 Publications Verification SC9420	Mineralocorticoid Receptor Androgen Receptor Autophagy	Metabolic Disease Cancer
Spironolactone (SC9420) is an orally active aldosterone mineralocorticoid receptor antagonist with an IC₅₀ of 24 nM. Spironolactone is also a potent antagonist of androgen receptor with an IC₅₀ of 77 nM. Spironolactone promotes autophagy in podocytes .

HY-N4170

Chebulic acid 1 Publications Verification	Others	Metabolic Disease
Chebulic acid, a phenolcarboxylic acid compound isolated from Terminalia chebula, has potent anti-oxidant activity, which breaks the cross-links of proteins induced by advanced glycation end-products (AGEs) and inhibits the formation of AGEs. Chebulic acid is effective in controlling elevated metabolic parameters, oxidative stress and renal damage, supporting its beneficial effect in diabetic nephropathy .

HY-145552A

Azilsartan mepixetil potassium QR-01019K	Angiotensin Receptor	Metabolic Disease
Azilsartan mepixetil potassium (QR-01019K) is the antagonist of angiotensin II receptor. Azilsartan mepixetil potassium has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil potassium has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A) .

HY-P1839

Angiotensin I/II (1-5)	Angiotensin Receptor	Cardiovascular Disease
Angiotensin I/II 1-5 is a peptide that contains the amino acids 1-5, which is converted from Angiotensin I/II. Angiotensin I is formed by the action of renin on angiotensinogen. Angiotensin II is produced from angiotensin I. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy .

HY-N0188

Esculin 3 Publications Verification	p38 MAPK	Inflammation/Immunology Cancer
Esculin is a fluorescent coumarin glucoside, the active ingredient in ash bark. Esculin has antidiabetic effects, improves cognitive impairment in experimental diabetic nephropathy (DN) via the MAPK signaling pathway, and exerts antioxidant stress and anti-inflammatory effects. Esculin also has anticancer, antibacterial, antiviral, neuroprotective, antithrombotic, and therapeutic properties for eye diseases .

HY-P1839A

Angiotensin I/II (1-5) (TFA)	Angiotensin Receptor	Cardiovascular Disease
Angiotensin I/II 1-5 TFA is a peptide that contains the amino acids 1-5, which is converted from Angiotensin I/II. Angiotensin I is formed by the action of renin on angiotensinogen. Angiotensin II is produced from angiotensin I. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy .

HY-109041

Razuprotafib 1 Publications Verification AKB-9778	Phosphatase Tie	Inflammation/Immunology
Razuprotafib (AKB-9778) is a potent and selective inhibitor of the catalytic activity of VE-PTP (vascular endothelial protein tyrosine phosphatase) with an IC₅₀of 17 pM. Razuprotafib promotes TIE2 activation, enhances ANG1-induced TIE2 activation, and stimulates phosphorylation of signaling molecules in the TIE2 pathway, including AKT, eNOS, and ERK. Razuprotafib inhibits the structurally related phosphatase PTP1B with an IC₅₀ of 780 nM. Razuprotafib shows excellent selectivity for VE-PTP versus a variety of phosphatases, with the exception of HPTPη (IC₅₀=36 pM) and HPTPγ (100 pM) .

HY-P1829

Angiotensin I/II (1-6)	Angiotensin Receptor	Cardiovascular Disease
Angiotensin I/II 1-6 contains the amino acids 1-6 and is converted from Angiotensin I/II peptide. The precursor angiotensinogen is cleaved by renin to form angiotensin I. Angiotensin I ishydrolyzed by angiotensin-converting enzyme (ACE) to form the biologically active angiotensin II. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy .

HY-P1829A

Angiotensin I/II (1-6) (TFA)	Angiotensin Receptor	Cardiovascular Disease
Angiotensin I/II (1-6) TFA contains the amino acids 1-6 and is converted from Angiotensin I/II peptide. The precursor angiotensinogen is cleaved by renin to form angiotensin I. Angiotensin I ishydrolyzed by angiotensin-converting enzyme (ACE) to form the biologically active angiotensin II. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy .

HY-124489

2-Hydroxyestradiol	Endogenous Metabolite	Metabolic Disease
2-Hydroxyestradiol, a metabolite of 17β-estradiol with minimal estrogenic activity, possesses antioxidant effects and reacts with DNA to form stable adducts and exerts genotoxicity .

HY-N2181

Acetylshikonin 1 Publications Verification
Acetylshikonin is an oral active anti-cancer, anti-inflammatory, antioxidant, anti-fertility, antibacterial, and neuroprotective agent. Acetylshikonin is a inhibitor of acetylcholinase (AChE) (IC₅₀=34.6 μM) and nonselective cytochrome P450. Acetylshikonin can induce Apoptosis and Autophagy in cancer cells. Acetylshikonin regulates blood glucose, liver fat metabolism, and renal fibrosis, and is used in the study of diabetes, diabetic nephropathy (DN), obesity, and nonalcoholic fatty liver disease (NAFLD) .

HY-18758

IN-1130
IN-1130 is a highly selective transforming growth factor-β type I receptor kinase (ALK5) inhibitor with an IC₅₀ of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC₅₀=36 nM) and p38α mitogen-activated protein kinase (IC₅₀=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis .

HY-135772

12-Ketodeoxycholic acid 12-Ketolithocholic acid	Endogenous Metabolite	Metabolic Disease
12-Ketodeoxycholic acid (12-Ketolithocholic acid) is a bile acid, metabolite from kidney. 12-Ketodeoxycholic acid can be a detectable marker for evidence of kidney injury

HY-13306

Pyrintegrin 3 Publications Verification	Integrin	Metabolic Disease
Pyrintegrin is an β1-integrin agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival. Pyrintegrin enhances cell-extracellular matrix (ECM) adhesion-mediated integrin signaling. Pyrintegrin can be used as a podocyte-protective agent and has robustly adipogenic .

HY-113089

Epsilon-(gamma-glutamyl)-lysine H-Glu(H-Lys-OH)-OH; γ-Glu-ε-Lys	Endogenous Metabolite	Metabolic Disease
Epsilon-(gamma-glutamyl)-lysine is an N(6)-acyl-L-lysine derivative. The enzyme tissue transglutaminase (tTg) helps the formation of epsilon-(gamma-glutamyl)lysine bonds between ECM components in some disease, such as non-diabetic kidney, glaucoma filtration .

Cat. No.	Product Name	Target	Research Area

HY-112431A

Carnostatine hydrochloride SAN9812 hydrochloride	Peptides	Metabolic Disease
Carnostatine hydrochloride (SAN9812 hydrochloride) is a potent and selective carnosinase 1 (CN1) inhibitor with a K_i of 11 nM for human recombinant CN1. Carnostatine hydrochloride can be used for the treatment of diabetic nephropathy (DN) .

HY-P5309

(Thr(GalNAc)4,7,15,Ser(GalNAc)9,11)-IgA1 Hinge Region Peptide	Biochemical Assay Reagents	Inflammation/Immunology
(Thr(GalNAc)4,7,15,Ser(GalNAc)9,11)-IgA1 Hinge Region Peptide is a synthetic glycopeptide and can be used for detection of gender difference and epitope specificity of IgG antibody activity against IgA1 hinge portion in IgA nephropathy patients .

HY-P5309A

(Thr(GalNAc)4,7,15,Ser(GalNAc)9,11)-IgA1 Hinge Region Peptide TFA	Peptides	Inflammation/Immunology
(Thr(GalNAc)4,7,15,Ser(GalNAc)9,11)-IgA1 Hinge Region Peptide (TFA) (GN5) is a synthetic glycopeptide and can be used for detection of gender difference and epitope specificity of IgG antibody activity against IgA1 hinge portion in IgA nephropathy patients .

HY-112431

Carnostatine SAN9812	Peptides	Metabolic Disease
Carnostatine (SAN9812) is a potent and selective carnosinase 1 (CN1) inhibitor with a K_i of 11 nM for human recombinant CN1. Carnostatine (SAN9812) can be used for the treatment of diabetic nephropathy (DN) .